Commonwealth Equity Services’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.29M | Sell |
|
|||||
|
2025
Q2 | $3.24M | Buy |
|
|||||
|
2025
Q1 | $2.29M | Buy |
|
|||||
|
2024
Q4 | $1.54M | Buy |
|
|||||
|
2024
Q3 | $1.46M | Sell |
|
|||||
|
2024
Q2 | $1.4M | Buy |
|
|||||
|
2024
Q1 | $836K | Buy |
|
|||||
|
2023
Q4 | $809K | Sell |
|
|||||
|
2023
Q3 | $774K | Buy |
|
|||||
|
2023
Q2 | $761K | Buy |
|
|||||
|
2023
Q1 | $733 | Sell |
|
|||||
|
2022
Q4 | $1.24M | Buy |
|
|||||
|
2022
Q3 | $955K | Buy |
|
|||||
|
2022
Q2 | $667K | Sell |
|
|||||
|
2022
Q1 | $819K | Sell |
|
|||||
|
2021
Q4 | $883K | Buy |
|
|||||
|
2021
Q3 | $806K | Sell |
|
|||||
|
2021
Q2 | $741K | Sell |
|
|||||
|
2021
Q1 | $679K | Buy |
|
|||||
|
2020
Q4 | $564K | Sell |
|
|||||
|
2020
Q3 | $632K | Buy |
|
|||||
|
2020
Q2 | $624K | Buy |
|
|||||
|
2020
Q1 | $449K | Sell |
|
|||||
|
2019
Q4 | $644K | Sell |
|
|||||
|
2019
Q3 | $567K | Sell |
|
|||||
|
2019
Q2 | $514K | Buy |
|
|||||
|
2019
Q1 | $656K | Sell |
|
|||||
|
2018
Q4 | $661K | Buy |
|
|||||
|
2018
Q3 | $286K | Buy |
|
|||||
|
2018
Q2 | $302K | Buy |
|
|||||
|
2018
Q1 | $352K | Sell |
|
|||||
|
2017
Q4 | $746K | Sell |
|
|||||
|
2017
Q3 | $826K | Sell |
|
|||||
|
2017
Q2 | $582K | Buy |
|
|||||
|
2017
Q1 | $328K | Sell |
|
|||||
|
2016
Q4 | $247K | Buy |
|
|||||
|
2016
Q3 | $393K | Buy |
|
|||||
|
2016
Q2 | $317K | Buy |
|